ÖÐɽ´óѧCell×Ó¿¯·¢²¼ÃâÒßгɹû
ÉúÎïͨ±¨µÀ À´×ÔÖÐɽ´óѧ¡¢ÐÝ˹¶ÙÎÀÀí¹«»áÒ½ÔºÑо¿ËùµÈ»ú¹¹µÄÑо¿ÈËԱ֤ʵ£¬TRIM11ͨ¹ýp62ÒÀÀµÐÔµÄÑ¡ÔñÐÔ×ÔÊɽµ½âAIM2ÒÖÖÆÁËAIM2Ñ×֢СÌå¡£ÕâÒ»Ñо¿·¢ÏÖ·¢²¼ÔÚ8ÔÂ4Èյġ¶Cell Reports¡·ÔÓÖ¾ÉÏ¡£
ÖÐɽ´óѧ½ÌÊÚ¡¢²©Ê¿Éúµ¼Ê¦´ÞöÁ£¨Jun Cui£©£¬ÓëÃÀ¹ú¿µÄζû´óѧÍþ¶ûҽѧԺ¡°SportѧºÍÃâÒßѧ¡±½ÌÊÚ£¬ÐÝ˹¶ÙÎÀÀí¹«»áÒ½ÔºÑо¿ËùÑ×Ö¢ºÍ±í¹ÛÒÅ´«Ñ§ÖÐÐÄÖ÷ÈÎÍõÈÙ¸££¨Rong-Fu Wang£©½ÌÊÚÊÇÕâÆªÂÛÎĵĹ²Í¬Í¨Ñ¶×÷Õß¡£´ÞöÁ½ÌÊÚ³¤ÆÚ´ÓʹÌÓÐÃâÒßϵͳʶ±ðºÍµ÷¿Ø¡¢ÐźÅתµ¼»úÖÆÓë¼²²¡Ïà¹ØÐÔÑо¿£¬ÔÚCell, Immunity, Nature immunologyµÈ¶¥¼¶ÔÓÖ¾·¢±íÁ˶àÏîÖØÒªµÄÑо¿ÂÛÎÄ¡£ÍõÈÙ¸£½ÌÊÚµÄÖ÷ÒªÑо¿·½Ïò°üÀ¨Ö×Áö¿¹Ô¼ø¶¨¡¢ÏÈÌìÃâÒß¡¢Ö×ÁöÃâÒßÖÎÁÆ£¬ÒÔ¼°¸Éϸ°ûºÍÖ×ÁöµÄ±í¹ÛÒÅ´«µ÷½Ú¡£
½ñÄê2Ô£¬´ÞöÁ½ÌÊÚºÍÍõÈÙ¸£½ÌÊÚ¿ÎÌâ×éºÏ×÷֤ʵ£¬TRIM9ͨ¹ýÕÐļGSK3¦Âµ½TBK1´¦ÓÅÏÈ´Ù½øÁËDNAºÍRNA²¡¶¾ÓÕµ¼Éú³ÉIÐ͸ÉÈÅËØ¡£ÕâÒ»Ñо¿·¢ÏÖ·¢²¼ÔÚ¡¶Cell Research¡·ÔÓÖ¾ÉÏ(ÖÐɽ´óѧ80ºó½ÌÊÚCellResearch·¢±íÖØÒªÑо¿³É¹û )¡£
Ñ×֢СÌåÊÇÔÚϸ°û¸ÐȾ»òѹÁ¦Çé¿öϼ¤»îµÄ·Ö×ÓÆ½Ì¨£¬ÆäÄܹ»´¥¶¯¼¤»î°ëë×°±Ëáµ°°×øcaspase-1£¬µ¼Ö´ÙÑ×֢ϸ°ûÒò×ÓIL-1¦ÂºÍIL-18³ÉÊìÓë·ÖÃÚ¡£×é×°Ñ×֢СÌåÐèÒªASCµ°°×¡¢caspase-1/caspase-11ºÍÖ§¼Üµ°°×¡£´ó¶àÊýµÄÖ§¼Üµ°°×¶¼ÊÇNodÑùÊÜÌå(NLRs)£¬ÀýÈçNLRp1¡¢NLRp3¡¢NLRp6, ºÍ NLRC4¡£Ñо¿Ö¤Êµ£¬AIM2ºÍIFI16¿É´¥·¢ÐγÉÑ×֢СÌå·Ö±ð¶Ô¿¹°ûÖÊ»òϸ°ûºËÖеÄÍâÔ´DNA¡£
LentiBrite™ Lentiviral Biosensorsʵʱ¼à²âϸ°û×ÔÊÉ£¬×ÔÊÉСÌ徫ȷ¶¨Î»
AIM2ÊÇpHYINµ°°×¼Ò×åµÄ³ÉÔ±¡£AIM2Ö÷Òª¶¨Î»ÓÚ°ûÖÊÄÚ£¬N¶Ëº¬Ò»¸öpYD½á¹¹Óò£¨pyrin domain£©£¬C¶ËΪHIN-200½á¹¹Óò¡£µ±AIM2µÄHIN-200½á¹¹ÓòÔÚ°ûÖÊÄÚ½áºÏË«Á´ DNAºó£¬ÊÍ·ÅpYD¶øÕÐļ½ÓÍ·µ°°×ASC£¬²¢ÓÕµ¼ÁËÑ×ÐÔСÌåµÄ×é×°£¬´Ó¶øÒýÆðCaspase-1µÄ¼¤»îÒÔ¼°IL-1¦ÂºÍIL-18µÄ³ÉÊìºÍ·ÖÃÚ¡£AIM2Ñ×֢СÌå»îÐÔʧµ÷Óë¸÷ÖÖ¼²²¡£¬ÀýÈçѪ¹ÜÑ×Ö¢¡¢ÒøÐ¼²¡¡¢»¯Å§ÐԹؽÚÑס¢»µ¾ÒÐÔŧƤ²¡¡¢ÒþÈȵ°°×-Ïà¹ØÖÜÆÚ×ÛºÏÕ÷(CApS)¾ùÓйØÁª¡£µ«Ä¿Ç°¶ÔÓÚAIM2Ñ×֢СÌåµÄÈ·Çе÷¿Ø»úÖÆÈÔ²»ÊǺÜÇå³þ¡£
ÔÚÕâÆªÎÄÕÂÖÐÑо¿ÈËԱ֤ʵ£¬TRIM11ÊÇAIM2Ñ×֢СÌåµÄÒ»¸ö¹Ø¼ü¸ºµ÷¿ØÒò×Ó¡£ÔÚDNA²¡¶¾¸ÐȾµÄÇé¿öÏ£¬TRIM11ͨ¹ýËüµÄpS½á¹¹Óò½áºÏAIM2£¬¾ÀúK458λµã×Ô¶à¾Û·ºËØ»¯£¬´Ù½øÁËTRIM11Óë×ÔÊÉ»õÎïÊÜÌåp62½áºÏ£¬Í¨¹ýÑ¡ÔñÐÔ×ÔÊɽ鵼ÁËAIM2½µ½â¡£ÕâЩÑо¿½á¹ûÈ·¶¨ÁËTRIMsÔÚAIM2Ñ×֢СÌ弤»îÖÐËùÆðµÄ×÷ÓãºTRIM11×÷Ϊ´Î¼¶ÊÜÌ彫AIM2´«Ë͵½×ÔÊÉСÌå´¦£¬ÒÔÒ»ÖÖp62ÒÀÀµÐÔ·½Ê½½éµ¼ÁËAIM2½µ½â¡£
2009Ä꣬ÍÐÂí˹½Ü¸¥Ñ·´óѧ´óѧKimmel°©Ö¢Ñо¿Ëùϸ°ûµòÍöÑо¿ÖÐÐÄÉúÎﻯѧÓë·Ö×ÓÉúÎïѧϵµÄÑо¿Ð¡×éÔÚϸ°ûµòÍö·½ÃæµÄÑо¿È¡µÃеĽøÕ¹£¬Ö¤ÊµÏ¸°ûÖÊDNA¿ÉÓÕµ¼AIM2¹Ñ¾Û»¯´ÙʹAIM2Ñ×Ö¢·´Ó¦¸´ºÏÎïÐγɣ¬±íÃ÷AIM2ÊÇÒ»¸öÖØÒªµÄÑ×Ö¢·´Ó¦ÎËü¿É¼¤»îASC pyroptosomeºÍCaspase-1¡£Ïà¹Ø³É¹û¹«²¼ÔÚ1ÔÂ22ÈÕNatureÔÓÖ¾ÉÏ(Nature£º×îÐÂϸ°ûµòÍö»úÖÆ)¡£
2012Ä꣬±±¾©ÉúÃü¿ÆÑ§Ñо¿ËùµÄÑо¿ÈËÔ±Ê״ᨵÀÁË·ÎÑ×¾üÍžú¿ÉÒÔͨ¹ýÆäËÄÐÍ·ÖÃÚϵͳÏòËÞÖ÷ϸ°û×¢ÈëÒ»¸öЧӦµ°°×·Ö×Ó£¬¸ÃЧӦµ°°××÷ÓõĽá¹û¿ÉÒÔ±ÜÃâ¾üÍžú±»ËÞÖ÷AIM2Ñ×֢СÌåÌìÈ»ÃâÒßϵͳËùʶ±ð¡£Ïà¹Ø³É¹û¹«²¼ÔÚpNASÔÓÖ¾ÉÏ(ÉÛ·å×é×îÐÂpNASÎÄÕ )¡£
À´×ÔSt. Jude¶ùͯҽԺµÄ¿ÆÑ§¼ÒÃÇ·¢ÏÖ£¬Ò»ÖÖ½Ð×öAIM2µÄÃâÒßϵͳµ°°×ÔÚ¾ö¶¨´ó³¦°©µÄÇÖÏ®ÐÔÖз¢»ÓÖØÒª×÷Óá£ËûÃÇ·¢ÏÖAIM2ȱʧ¿Éµ¼Ö³¦Ï¸°ûʧ¿ØÐÔÔöÖ³¡£ÁîÈ˾ªÑȵØÊÇ£¬ËûÃÇ»¹·¢ÏÖAIM2Ó°ÏìÁ˳¦µÀSportȺ£¬Ëƺõ´Ù½øÁËÔ¤·À´ó³¦°©µÄ¡°ºÃ¡±Ï¸¾úÔöÖ³¡£Ñо¿½á¹û·¢²¼ÔÚ2015Äê6ÔµÄCellÔÓÖ¾ÉÏ(Cell·¢Ïִ󳦰©µÄаеã)¡£
£¨ÉúÎïͨ£ººÎæÍ£©
ÉúÎïÍ¨ÍÆ¼öÔÎÄÕªÒª£º
TRIM11 Suppresses AIM2 Inflammasome by Degrading AIM2 via p62-Dependent Selective Autophagy
The AIM2 inflammasome is a key cytosolic signaling complex that is activated by double-stranded DNA, leading to the maturation of proinflammatory cytokines such as interleukin-1¦Â (IL-1¦Â) and IL-18. Dysregulated AIM2 inflammasome activity is associated with human inflammatory diseases and cancers, suggesting that its activity must be tightly regulated. However, the precise molecular mechanisms that control AIM2 levels and activity are still poorly understood. Here, we report tripartite motif 11 (TRIM11) as a key negative regulator of the AIM2 inflammasome. Upon DNA virus infection, TRIM11 binds to AIM2 via its pS domain and undergoes auto-polyubiquitination at K458 to promote an association between TRIM11 and the autophagic cargo receptor p62 to mediate AIM2 degradation via selective autophagy. These findings identify a role for TRIMs in AIM2 inflammasome activation where TRIM11 acts as a secondary receptor to deliver AIM2 to the autophagosomes for degradation in a p62-dependent manner.
×÷Õß¼ò½é£º
´ÞöÁ
1982ÄêÉú¡£ÖÐɽ´óѧÉúÃü¿ÆÑ§Ñ§Ôº½ÌÊÚ¡¢²©Ê¿Éúµ¼Ê¦¡£2012ÄêÈëÑ¡ÖÐɽ´óѧ¡°****¡±¡£´ÞöÁ½ÌÊÚ³¤ÆÚ´ÓʹÌÓÐÃâÒßϵͳʶ±ðºÍµ÷¿Ø¡¢ÐźÅתµ¼»úÖÆÓë¼²²¡Ïà¹ØÐÔÑо¿£¬ÔÚʵÑéÉúÎïѧ£¨ÌرðÊÇ·Ö×ÓÃâÒßѧ£©ºÍ¼ÆËãÉúÎïѧ£¨ÉúÎïÐźŴ«µ¼ÍøÂçµÄÊýѧģÐͽ¨Á¢£©ÁìÓò¾ù×ö³öÁ˶àÏî½Ü³ö¹¤×÷¡£
ÍõÈÙ¸£½ÌÊÚ
ÃÀ¹ú¿µÄζû´óѧÍþ¶ûҽѧԺ¡°SportѧºÍÃâÒßѧ¡±½ÌÊÚ£¬ÐÝ˹¶ÙÎÀÀí¹«»áÒ½ÔºÑо¿ËùÑ×Ö¢ºÍ±í¹ÛÒÅ´«Ñ§ÖÐÐÄÖ÷ÈΡ£1992ÄêÔÚÃÀ¹ú×ôÖÎÑÇ´óѧ»ñµÃ²©Ê¿Ñ§Î»¡£ÔÚ˹̹¸£´óѧҽѧԺÍê³ÉÆä²©Ê¿ºóÑо¿ºó£¬¼ÓÈëÁËÃÀ¹ú¹ú¼ÒÖ×ÁöÑо¿ËùÍâ¿Æ×飬ÓëDr. Steve RosernbergÒ»Æð¹¤×÷£¬Ö®ºó½úÉýΪ¸ß¼¶Ñо¿Ô±¡£2000Ä꣬Ëû¿ªÊ¼ÔÚ±´ÀÕҽѧԺµ£Èθ±½ÌÊÚ£¬2004Äê½úÉýΪ²¡ÀíºÍÃâÒßϵÒÔ¼°Ï¸°ûºÍ»ùÒòÖÎÁÆÖÐÐĽÌÊÚ¡£2007Äê±»ÊÚÓèJack L. Titus½ÌÊÚְλ¡£2011Ä꿪ʼÔÚ¿µÄζû´óѧÍþ¶ûҽѧԺ¸½ÊôÎÀÀí¹«»áÒ½ÔºÑо¿Ëù¹¤×÷£¬Ä¿Ç°µ£ÈÎÑ×Ö¢ºÍ±í¹ÛÒÅ´«Ñ§ÖÐÐÄÖ÷Èμ°½ÌÊÚ¡¢ÌÇÄò²¡Ñо¿ÖÐÐÄÖ÷ÈΡ£ËûÔÚÖ×Áö¿¹Ô¼ø¶¨¡¢ÏÈÌìÃâÒß¡¢Ö×ÁöÃâÒßÖÎÁÆ£¬ÒÔ¼°¸Éϸ°ûºÍÖ×ÁöµÄ±í¹ÛÒÅ´«µ÷½Ú·½ÃæÓÐ×ų¤ÆÚÎȶ¨µÄÑо¿ÐËȤ¡£